Log in to save to my catalogue

Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0f1a3024ff0545aa82f9b9336c33d917

Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

About 50% of hospitalized coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM) developed myocardial damage. The mechanisms of direct SARS-CoV-2 cardiomyocyte infection include viral invasion via ACE2-Spike glycoprotein-binding. In DM patients, the impact of glycation of ACE2 on cardiomyocyte invasion by SARS-CoV-2 can be of high...

Alternative Titles

Full title

Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_0f1a3024ff0545aa82f9b9336c33d917

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0f1a3024ff0545aa82f9b9336c33d917

Other Identifiers

ISSN

1475-2840

E-ISSN

1475-2840

DOI

10.1186/s12933-021-01286-7

How to access this item